A trial of TACE, pembrolizumab and lenvatinib for cancer of the liver (LEAP-012)

This trial is looking at adding pembrolizumab and lenvatinib to TACE to improve treatment for liver cancer.

TACE gives high doses of chemotherapy to the tumour in the liver and blocks off the blood supply.

This trial is for people who have:

• a type of liver cancer called hepatocellular carcinoma (HCC) and

• whose cancer hasn’t spread elsewhere in the body